Xtandi®

Active substance

enzalutamide

Holder

Astellas Pharma BV

Status

closed

Indication

treatment of adult men with metastatic hormone‐sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (pending final marketing authorisation)

Public documents

Approbation

Approbation Amendment 1

Approbation Amendment 2

Information for the patient

Information for the patient Amendment 1

Information for the patient Amendment 2

Informed consent

Informed consent Amendment 1

Last update

08/10/2022